Lataa...
Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer
Combination chemotherapy has been proven to be an efficient strategy for the treatment of prostate cancer (PCA). However, the pharmacokinetic distinction between the relevant drugs is an insurmountable barrier to the realization of their synergistic use against cancer. To overcome the disadvantages...
Tallennettuna:
| Julkaisussa: | Front Pharmacol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6930690/ https://ncbi.nlm.nih.gov/pubmed/31920642 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.01436 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|